Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Erlotinib in Advanced Pancreatic Cancer

Erlotinib in Advanced Pancreatic Cancer Am J Cancer 2006; 5 (1): 41-42 GUEST COMMENTARIES 1175-6357/06/0001-0041/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. tions in patients who received erlotinib compared with those who received placebo. This improvement was associated with a modest A Viewpoint by Henry Q. Xiong increase of toxicity, primarily skin rash and diarrhea. Department of Gastrointestinal Medical Oncology, The This was the first demonstration that adding the small molecule University of Texas M. D. Anderson Cancer Center, Houston, EGFR inhibitor erlotinib to a chemotherapy regimen improves Texas, USA survival in the clinical setting. Erlotinib in combination with Treatment options for advanced pancreatic cancer are very gemcitabine is now indicated in patients with advanced pancreatic limited. Gemcitabine, the most commonly used chemotherapy cancer and is a welcome additional regimen for patients whose drug, offers improvement of cancer-related symptoms and mod- treatment options remain extremely limited. However, because the estly prolongs life. There is a great need to develop novel therapies demonstrated benefit of erlotinib was disappointingly small, one for advanced pancreatic cancer. wonders if this statistically significant difference will make a One such therapeutic approach is to combine gemcitabine with clinical difference. molecular targeted agents. Erlotinib, like many small molecule Such http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Erlotinib in Advanced Pancreatic Cancer

American Journal of Cancer , Volume 5 (1) – Aug 10, 2012

Erlotinib in Advanced Pancreatic Cancer

Abstract

Am J Cancer 2006; 5 (1): 41-42 GUEST COMMENTARIES 1175-6357/06/0001-0041/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. tions in patients who received erlotinib compared with those who received placebo. This improvement was associated with a modest A Viewpoint by Henry Q. Xiong increase of toxicity, primarily skin rash and diarrhea. Department of Gastrointestinal Medical Oncology, The This was the first demonstration that adding the small molecule University of Texas M....
Loading next page...
 
/lp/springer-journals/erlotinib-in-advanced-pancreatic-cancer-8D8VeuPiLt
Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200605010-00007
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2006; 5 (1): 41-42 GUEST COMMENTARIES 1175-6357/06/0001-0041/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. tions in patients who received erlotinib compared with those who received placebo. This improvement was associated with a modest A Viewpoint by Henry Q. Xiong increase of toxicity, primarily skin rash and diarrhea. Department of Gastrointestinal Medical Oncology, The This was the first demonstration that adding the small molecule University of Texas M. D. Anderson Cancer Center, Houston, EGFR inhibitor erlotinib to a chemotherapy regimen improves Texas, USA survival in the clinical setting. Erlotinib in combination with Treatment options for advanced pancreatic cancer are very gemcitabine is now indicated in patients with advanced pancreatic limited. Gemcitabine, the most commonly used chemotherapy cancer and is a welcome additional regimen for patients whose drug, offers improvement of cancer-related symptoms and mod- treatment options remain extremely limited. However, because the estly prolongs life. There is a great need to develop novel therapies demonstrated benefit of erlotinib was disappointingly small, one for advanced pancreatic cancer. wonders if this statistically significant difference will make a One such therapeutic approach is to combine gemcitabine with clinical difference. molecular targeted agents. Erlotinib, like many small molecule Such

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

There are no references for this article.